Postpartum depression
Drug research and approvals for postpartum depression: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 88 studies of postpartum depression are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 88
- Trials authorized in Canada: 4
- FDA orphan approvals: 0
- EU medicines: 1
- Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum DepressionNCT07925762 · Not applicable · University of Sao Paulo · starts Sep 9, 2026
- Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum DepressionNCT07919392 · Not applicable · Ohio State University · starts Jul 24, 2026
- A Web-based Intervention Program for Postpartum DepressionNCT07902141 · Early Phase 1 · Babes-Bolyai University · starts Oct 27, 2026
- Methyl Donor-Rich Diet in the Postpartum PeriodNCT07887178 · Not applicable · Istanbul University - Cerrahpasa · starts May 21, 2026
- Brexanolone Lifting Outcomes Of MomsNCT07822321 · Phase 3 · Lipocine Inc. · starts Sep 1, 2026
- Effect of Peripartum 40 Hz Audiovisual Stimulation on Postpartum Depression in Women Undergoing Elective Cesarean…NCT07807462 · Not applicable · The First People's Hospital of Lianyungang · starts Oct 1, 2026
- Deconstructing Maternal Burdens: Doulas and the Community Unite for HealthNCT07799805 · Not applicable · University of Florida · starts Sep 15, 2026
- The Goal is to Examine the Impact of Doula-delivered, Nurse-coordinated Postpartum Care Among Individuals With Preterm…NCT07787845 · Not applicable · University of South Carolina · starts Oct 21, 2026
- Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal DepressionNCT07774559 · Not applicable · Psychiatric University Hospital, Zurich · starts Oct 27, 2026
Approved 2
- BrexanoloneGABA-A receptor; anion channel positive allosteric modulator
- ZuranoloneGABA-A receptor; anion channel positive allosteric modulator
Phase 3 3
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- AripiprazoleDopamine D2 receptor partial agonist
- CelecoxibCyclooxygenase-2 inhibitor
Phase 2 5
- ProgesteroneProgesterone receptor agonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- SertralineSerotonin transporter inhibitor
- LeuprolideGonadotropin-releasing hormone receptor agonist
- Omega-3-ACID ethyl esters
Phase 1 or earlier 1
- TrazodoneSerotonin transporter inhibitor
How its trials ended
447 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 68 whose ending is known, 54% met their primary endpoint, 9% missed it and 37% stopped early.
- Completed, result not reported20446%
- Ongoing12428%
- Status unknown5111%
- Met its primary endpoint378%
- Stopped: other or unclear153%
- Missed its primary endpoint61%
- Stopped: enrollment or feasibility61%
- Stopped: sponsor or business decision2<1%
- Stopped: funding2<1%
| Oct 23, 2024 | A double-blind, randomized trial of quetiapine versus trazadone in women with postpartum depressionTrazodone / Quetiapine | Dr Verinder Sharma | Closed |
| Jul 22, 2021 | A pilot study on the safety, tolerability, and effectiveness of quetiapine in postpartum depressionQuetiapine | Lawson Health Research Institute | Ongoing |
| Sep 22, 2016 | Adjunctive use of celecoxib in the treatment of bipolar postpartum depression: a randomized, double-blind, placebo controlled trialCelecoxib | Dr Verinder Sharma | Pending |
| Jun 8, 2016 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and pharmacokinetics of SAGE-547 injection…Allopregnanolone (SAGE-547, brexanolone) | Sage Therapeutics | Pending |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| not available | ZurzuvaeZuranolone | Biogen Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA